The current WHO classification recommends testing for CDKN2A/B homozygous deletion in IDH-mut astrocytomas that exhibit anaplastic characteristics of CNS WHO grade 3. The gene discussed is IDH1; the disease is astrocytoma (excluding glioblastoma).